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We investigated the effects of chronic subcutaneous treatment with centrally-acting
antihypertensive agents moxonidine, rilmenidine, and clonidine on the baroreflex control
of heart rate (HR) in conscious normotensive rabbits over 3 weeks. Infusions of
phenylephrine and nitroprusside were performed at week 0 and at weeks 1 and 3
of treatment to determine mean arterial pressure (MAP)-HR baroreflex relationships.
A second curve was performed after intravenous methscopolamine to determine the
sympathetic baroreflex relationship. The vagal component of the reflex was determined
by subtracting the sympathetic curve from the intact curve. Clonidine and moxonidine
(both 1 mg/kg/day), and rilmenidine (5 mg/kg/day), reduced MAP by 13 ± 3, 15 ± 2,
and 13 ± 2 mmHg, respectively, but had no effect on HR over the 3-week treatment
period. Whilst all three antihypertensive agents shifted baroreflex curves to the left,
parallel to the degree of hypotension, moxonidine and rilmenidine decreased the vagal
contribution to the baroreflex by decreasing the HR range of the reflex but moxonidine
also increased sympathetic baroreflex range and sensitivity. By contrast clonidine had
little chronic effect on the cardiac baroreflex. The present study shows that second
generation agents moxonidine and rilmenidine but not first generation agent clonidine
chronically shift the balance of baroreflex control of HR toward greater sympathetic and
lesser vagal influences. These changes if translated to hypertensive subjects, may not
be particularly helpful in view of the already reduced vagal contribution in hypertension.
Keywords: moxonidine, rilmenidine, clonidine, baroreceptor-heart rate reflex, blood pressure, conscious rabbits,
cardiac vagus, cardiac sympathetic
INTRODUCTION
Much evidence now supports the view that neural control of the circulation via the sympathetic
nervous system is heightened early in the development of hypertension which may well contribute
to severity of the disease (Esler et al., 1981; Julius and Weder, 1989). Overall sympathetic activity
is not generally altered but is elevated to specific organs such as the kidney and heart in young
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patients with borderline hypertension (Esler et al., 1988).
Furthermore, it is now well established that in chronically
hypertensive man and animals there are diminished baroreceptor
reflexes (Andresen et al., 1980; Mancia et al., 1986; Korner, 1989).
Baroreflex control of heart rate (HR) and vasoconstrictor tone
act to keep blood pressure (BP) close to a particular set point in
the short term with the rapid resetting of arterial baroreceptor
afferents toward any sustained new level of pressure, ensuring
the reflex effectively buffers moment to moment changes in BP
(Guyton, 1991). The diminished baroreflex control of HR in
hypertensive subjects is of concern since recent studies have
shown that this is an independent risk factor for acute myocardial
infarction (Farrell et al., 1991; Fei et al., 1994). Given the
increased sympathetic nervous activity to the kidney and heart
and diminished baroreflex control in hypertension, there is a
great deal of merit in antihypertensive treatments which not
only reduce BP by reducing sympathetic outflow, but restore the
baroreflex deficit.
Centrally acting antihypertensive agents, first introduced for
clinical use in the early 1960’s, reduce arterial pressure by
decreasing sympathetic vasomotor activity (Kobinger, 1978)
and have been shown to increase the sensitivity of the
vagal baroreceptor-HR reflex in animals (Badoer et al., 1983).



















FIGURE 1 | Average sigmoid curves indicating the relationship between mean arterial pressure (MAP, mmHg) and heart rate (HR, beats/min) for the
intact baroreflex curves (left panel) and the sympathetic and calculated vagal baroreflex curves (right panel) in six conscious rabbits before (weeks 0,
black line, black circles on all panels) and at weeks 1 (blue line, blue square on all panels) and 3 (red line, red triangle on all panels) of moxonidine
treatment. Symbols on curves represent resting values. Error bars are average SEM indicating variation between animals calculated from the ANOVA.
were α-methyldopa (a phenylethylamine) and clonidine (an
imidazoline). Although, their mechanism of action was originally
thought to involve α2-adrenoceptors, in1984, Bousquet et al.
suggested that the antihypertensive effect of clonidine was more
related to its imidazoline structure and suggested an action
at a distinct class of receptor with affinity for imidazoline
compounds, hence named the “imidazoline receptor” (Bousquet
et al., 1984). Despite its effective antihypertensive action,
clonidine also induces a high frequency of untoward side
effects, including sedation, dry mouth, headache, depression and
orthostatic hypotension (Ollivier and Christen, 1994). These
effects are thought to be due to the activation of α2-adrenoceptors
(Schmitt, 1977; Tibirica et al., 1989) and have limited the
therapeutic potential of clonidine. Subsequently, substances with
greater selectivity for imidazoline receptors were sought for
use as antihypertensive agents, to reduce BP by reducing the
sympathetic overactivity seen in hypertension but also to reduce
side effects.
Second generation centrally acting antihypertensive agents,
such as rilmenidine (an oxazoline, related structurally to
imidazoline) and moxonidine (an imidazoline), were developed
and found to possess a 30–60-fold higher selectivity for
imidazoline sites over α2-adrenoceptors (Ernsberger et al.,
1992). As such, these agents are more tolerable than clonidine,
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causing fewer side effects (Ollivier and Christen, 1994) with the
absence of rebound hypertension upon withdrawal (Sannajust
et al., 1989; Ollivier and Christen, 1994). They both induce
falls in BP by activating imidazoline receptors in the rostral
ventrolateral medulla to reduce sympathetic outflow, whilst
rilmenidine inhibits the cardiac sympathetic baroreflex response
and moxonidine inhibits the vagal component of the reflex
(Head et al., 1997). This effectiveness in lowering BP combined
with their longer half-lives makes them much more useful
therapeutically than clonidine (Plänitz, 1984; Fillastre et al.,
1988; Ostermann et al., 1988). Surprisingly, evidence for effects
these centrally acting agents have on baroreflex curves is
based almost entirely on acute administration of moxonidine
(Khokhlova et al., 2001; Ma et al., 2007; Turcani, 2008),
rilmenidine and clonidine rather than chronic administration,
which is perhaps more relevant to long term therapy. There
is one early study in conscious dogs using chronic but bolus
dosing with rilmenidine (Spiers et al., 1990). Thus, the present
study was designed to investigate and compare the effects of
moxonidine, rilmenidine and clonidine on the baroreflex control




A total of 21 normotensive rabbits of either sex, derived from a
multi-colored English stock maintained at the Baker IDI Heart
and Diabetes Institute, each with body weight between 2.4 and
2.9 kg were included in the study. Experiments were performed
in accordance with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes (1990) and were
approved by the Animal Experimental Committee of the Baker
Institute/Alfred Medical Research and Education Precinct.
Chronic Antihypertensive Treatment
Rabbits were chronically infused with subcutaneous moxonidine
(1 mg/kg/day, n = 6), rilmenidine (5 mg/kg/day, n = 8),
clonidine (1mg/kg/day, n = 7) or saline vehicle (n = 7)
for 3 weeks, at a constant rate of 5µl/h. These doses were
effective chronically as determined previously (Parkin et al.,
2003). Moxonidine infusions were directly preceded by an initial
280µg/kg intravenous bolus due to its slow onset of action.
Infusions were achieved using osmotic minipumps (Model



















FIGURE 2 | Average sigmoid curves indicating the relationship between mean arterial pressure (MAP, mmHg) and heart rate (HR, beats/min) for the
intact baroreflex curves (left panel) and the sympathetic and calculated vagal baroreflex curves (right panel) in eight conscious rabbits before (weeks
0, black line, black circles on all panels) and at weeks 1 (blue line, blue square on all panels) and 3 (red line, red triangle on all panels) of rilmenidine
treatment. Symbols on curves represent resting values. Error bars are average SEM indicating variation between animals calculated from the ANOVA.
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the shoulder blades under local anesthetic (1% lignocaine HCL,
Citanest, Astra Pharmaceuticals, North Ryde, New South Wales,
Australia). Each minipump lasted 2 weeks, at which point the
pumps were replaced to achieve a 3-week infusion regime. Of the
21 rabbits, 14 received one treatment whilst 7 entered a second
treatment period, with a different agent, after a minimum wash-
out period of 2 weeks. Three other rabbits did not complete the
study for reasons unrelated to the treatments, such as minipump
failure and were not included in the study results.
Cardiovascular Measurements
On each experimental day, the rabbit was placed in a wooden
box designed to hold one rabbit. Minor preparatory procedures
were performed under local anesthesia with 1% lignocaine HCL
(Citanest; Astra Pharmaceuticals). The marginal ear vein was
cannulated with a 24-gauge, 19mm Teflon catheter (Insyte;
Deseret Medical, Sansy, Utah, USA) for injections of vasoactive
drugs and methscopolamine, as appropriate, and the central
ear artery was cannulated with a 22-gauge, 25mm Teflon
catheter (Insyte) for measuring BP. The catheter was connected
to a Statham P23Dc pressure transducer (Gould Inc., Bernie,
Maryland, USA) for continuous measurements of arterial
pressure and HR. We allowed a 1 h period for the rabbits
to recover from the minor procedures before commencing the
experiment, to permit stabilization of cardiovascular parameters.
The pulsatile arterial pressure was dampened to derive the mean
arterial pressure (MAP) whereas the HR was measured using
a HR meter triggered from the arterial pulse. The MAP and
HR signals were digitized on-line using a National Instruments
data acquisition card (PC plus, Austin, Texas, USA) and a
data acquisition program designed using LabVIEW graphical
programming language (National Instruments, Austin, Texas,
USA). Software developed at the Baker IDI Heart and Diabetes
Institute was used to average and store the data over 2 s periods
for subsequent analysis.
Experimental Protocols
For each drug treatment period, rabbits were studied on three
separate occasions, day 0 (before treatment) and again at day
7 and day 21 (post treatment). Before commencement of each
experiment, body weights were noted to ensure good health. On
the first experimental day, Week 0, a pre-treatment baroreflex
curve was performed, after basal MAP and HR were recorded for
20–30min to yield control values. Following this, a minipump
containing either vehicle (saline). Moxonidine, rilmenidine or
clonidine was inserted between the shoulder blades for chronic
subcutaneous administration. At day 7 (referred to as week 1, for



















FIGURE 3 | Average sigmoid curves indicating the relationship between mean arterial pressure (MAP, mmHg) and heart rate (HR, beats/min) for the
intact baroreflex curves (left panel) and the sympathetic and calculated vagal baroreflex curves (right panel) in seven conscious rabbits before (weeks
0, black line, black circles on all panels) and at weeks 1 (blue line, blue square on all panels) and 3 (red line, red triangle on all panels) of clonidine
treatment. Symbols on curves represent resting values. Error bars are average SEM indicating variation between animals calculated from the ANOVA.
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TABLE 1 | Average basal values and baroreflex parameters describing intact, sympathetic and calculated vagal MAP-HR curves before and at weeks 1
and 3 of subcutaneous administration of moxonidine (n = 6).
Intact Sympathetic Calculated vagal
Week 0 Week 1 Week 3 Week 0 Week 1 Week 3 Week 0 Week 1 Week 3
BASAL PARAMETERS
MAP mmHg 78±3 68± 1** 69± 1** 81± 4 70± 1* 75±1* 76± 4 65±2** 63±2**
HR b/min 141±6 142± 12 140± 7 251± 7 206± 9*** 218±5*** 139± 14 137±9 129±12
BAROREFLEX PARAMETERS
Lower plateau, b/min 100±7 111± 10 100± 9 225± 12 195± 5* 208±3* 100± 7 111±10 100±9
Upper plateau, b/min 308±5 314± 8 314± 5 306± 7 309± 11 314±5 226± 11 200±11 222±20
Range, b/min 208±9 202± 8 214± 9 82± 12 114± 8* 107±6* 126± 13 89±14* 107±8*
BP50, mmHg 72±4 56± 2*** 60± 1*** 78± 4 59± 3** 64±1** 67± 6 49±5** 55±2**
Average gain, b/min/mmHg −8.0±1.2 −9.0± 1.2 −9.1± 1.3 −3.2± 0.7 −6.5± 1.1* −6.2±1.5* −4.8± 1.0 −2.5±1.4 −2.9±1.0
Goodness of fit 96±1 95± 1 96± 1 96± 1 96± 3 96±1
Values are mean ± between animal SEM. *P < 0.05, **P < 0.01 and *** P < 0.001 for the comparison between pre- and post-treatment. MAP, mean arterial pressure; HR, heart rate;
BP50, median blood pressure.
TABLE 2 | Average basal values and baroreflex parameters describing intact, sympathetic and calculated vagal MAP-HR curves before and at weeks 1
and 3 of subcutaneous administration of rilmenidine (n = 8).
Intact Sympathetic Calculated vagal
Week 0 Week 1 Week 3 Week 0 Week 1 Week 3 Week 0 Week 1 Week 3
BASAL PARAMETERS
MAP mmHg 77± 3 70± 4** 68± 3** 83± 1 71± 3** 73±4** 75±5 70±5* 65±4*
HR b/min 164± 10 147± 8 151± 10 279± 10 232± 8*** 246±10*** 163±12 156±7 153±11
BAROREFLEX PARAMETERS
Lower plateau, b/min 106± 6 114± 8 117± 10 261± 8 228± 11** 241±12** 106±6 114±8 117±10
Upper plateau, b/min 329± 9 315± 14* 305± 21* 330± 9 297± 13* 309±11* 260±9 250±14 237±17
Range, b/min 223± 10 205± 13** 188± 17** 69± 5 69± 13 67±14 154±9 136±13* 121±9*
BP50, mmHg 72± 4 58± 3*** 58± 3*** 77± 3 54± 3*** 59±5*** 70±5 58±5* 56±4*
Average gain, b/min/mmHg −8.9± 1.1 −7.6± 0.9 −7.7± 1.2 −3.4± 0.7 −4.0± 0.7 −2.5±0.7 −5.4±1.1 −3.5±0.8 −5.3±1.2
%Goodness of fit 97± 1 98± 1 97± 1 95± 2 95± 2 87±4
Values are mean ± between animal SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 for the comparison between pre- and post-treatment. MAP, mean arterial pressure; HR, heart rate;
BP50, median blood pressure.
and HR were recorded for 20–30min, the baroreflex curves were
again determined.
The before- and after-treatment MAP-HR baroreflex
relationships were assessed using the ramp method (Dorward
et al., 1985) over the full range of physiologically relevant
pressures. This method consisted of slow ramp falls and rises in
MAP by intravenous infusions of phenylephrine hydrochloride
(0.5mg/ml) and sodium nitroprusside (1.0mg/ml), respectively
and was done in duplicate. Infusions took 1–2min and the rate of
change of MAPwas kept between 1 and 2mmHg per second. The
sympathetic component of the reflex was then assessed during
vagal blockade with intravenous methscopolamine (63µg/kg
bolus + 2.5µg/kg/min infusion; 6ml/h). After a second 20
min control period, measuring MAP and HR, the sympathetic
baroreflex was assessed using the steady-state technique (Korner
et al., 1972). Multiple step increases and decreases in MAP
were reached and maintained constant for 20–30 s to allow the
HR to reach a steady-state response, induced by changes in
cardiac sympathetic activity. After generating the intact and
sympathetic baroreflex curves, the vagal component of the reflex
was determined by mathematically subtracting the sympathetic
curve from the intact curve as described previously (Godwin
et al., 1998). At week 2 of treatment, cardiovascular parameters
were measured to ensure that the antihypertensive agents were
still exhibiting an effect. Minipumps were also changed on this
day.
Analysis of MAP-HR Curves
MAP and HR values were binned into 2 s intervals and fitted
to a non-symmetrical sigmoid logistic function using a non-
linear least squares regression program based on the Marquardt-
Levenberg algorithm (Marquardt, 1963). The equation fitted was
y′ = P1+
P2
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TABLE 3 | Average basal values and baroreflex parameters describing intact, sympathetic and calculated vagal MAP-HR curves before and at weeks 1
and 3 of subcutaneous administration of clonidine (n = 7).
Intact Sympathetic Calculated vagal
Week 0 Week 1 Week 3 Week 0 Week 1 Week 3 Week 0 Week 1 Week 3
BASAL PARAMETERS
MAP mmHg 80± 2 72± 3* 74±3* 79± 1 79±6 82± 3 80± 3 69±3** 70± 4**
HR b/min 159± 8 166± 17 163±11 266± 12 224±12*** 236± 15*** 143± 10 170±20 171± 14
BAROREFLEX PARAMETERS
Lower plateau, b/min 106± 8 126± 12 123±10 245± 10 218±11* 229± 9* 106± 8 126±12 123± 10
Upper plateau, b/min 319± 8 321± 11 327±6 308± 8 280±9 292± 17 255± 7 259±10 264± 9
Range, b/min 213± 6 195± 10 203±6 63± 5 62±11 63± 10 149± 8 133±8 141± 12
BP50, mmHg 75± 2 59± 4*** 64±5*** 77± 2 62±7** 62± 5** 74± 2 55±5** 62± 6**
Average gain, b/min/mmHg −9.7± 0.8 −7.1± 1.0* −7.3±0.7* −2.2± 0.4 −4.9±2.0 −4.3± 0.8 −7.5± 1.0 −2.3±1.8*** −3.0± 0.6***
%Goodness of fit 98± 1 97± 1 98±1 97± 1 93±3 96± 2
Values are mean ± between animal SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 for the comparison between pre- and post-treatment. MAP, mean arterial pressure; HR, heart rate;
BP50, median blood pressure.
TABLE 4 | Average basal values and baroreflex parameters describing intact, sympathetic and calculated vagal MAP-HR curves before and at weeks 1
and 3 of subcutaneous administration of vehicle (n = 7).
Intact Sympathetic Calculated vagal
Week 0 Week 1 Week 3 Week 0 Week 1 Week 3 Week 0 Week 1 Week 3
BASAL PARAMETERS
MAP mmHg 78± 3 79±4 77± 2 79± 4 74±3 79± 4 77± 4 83±6 76±3
HR b/min 161± 10 180±14 162± 8 278± 12 263±9 271± 11 149± 7 160±14 161±9
BAROREFLEX PARAMETERS
Lower plateau, b/min 108± 9 108±17 112± 8 251± 13 243±11 242± 11 108± 9 108±17 112±8
Upper plateau, b/min 330± 9 324±12 320± 9 332± 10 324±11 328± 10 260± 15 244±14 234±12
Range, b/min 224± 14 216±15 208± 14 80± 9 81±6 86± 6 143± 20 136±16 122±15
BP50, mmHg 75± 3 74±3 74± 3 79± 6 73±4 79± 4 73± 5 76±4 71±4
Average gain, b/min/mmHg −10.9± 0.8 −9.1±1.4* −7.8± 0.6* −2.9± 0.7 −4.2±1.4 −3.5± 1.4 −8.0± 1.3 −4.6±1.8** −4.1±1.6**
Goodness of fit 98± 1 98±1 97± 1 95± 1 96±1 96± 1





1+ e−c¯f (P4− x′)
defines the function for smooth transition (between 0 and 1)
which is centered about the BP50. The average curvature of f is
given by
c¯f =
2 · P3 · P5
|P3+ P5|
where P1 is the lower plateau (LP, calculated minimum HR),
P2 is the difference between the lower plateau and the upper
plateau (calculated maximum HR) and P5 and P3 are curvature
parameters indicating the rate of change as the function
transitions to the plateau. P4 is the set point MAP at half the
HR range (BP50). The average gain of the curve (G) which is the
slope between the two inflection points of the curve is G=−P2×
(P3 + P5)/9.12. This logistic curve fitting routine was not forced
through the resting value thus allowing it to lie away from the line
of the baroreflex curve.
The contribution of the vagus was calculated as the
difference between the initial curve (vagus + sympathetic) and
the methscopolamine curve (sympathetic), calculated for each
animal (Head, 1994). Using conscious rats, we have shown that
the vagal and sympathetic components sum to produce a curve
very close to the real intact vagal and sympathetic curve (Head
and McCarty, 1987).
Vagal and Sympathetic Contribution to
Basal HR
The vagal and sympathetic contributions to the maintenance of
basal HR were calculated before treatment began and at weeks
1 and 3 of treatment for each experimental group, according
to the methods of Head and Adams (Head and Adams, 1992).
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Sympathetic HR was calculated as the HR after vagal blockade
(with an intravenous methscopolamine infusion) minus intrinsic
HR. The latter was estimated, according to the literature, as
200 b/min for rabbits at that body weight (Zola et al., 1988;
Opthof, 2000; Such et al., 2002). Vagal HR was calculated as the
HR after vagal blockade (sympathetic intact) minus basal HR
(vagal and sympathetic intact).
Data Analysis
Values are expressed as mean ± standard error of the mean
(SEM). Treatment effects were assessed by amulti-factor repeated
measure analysis of variance (ANOVA). The main effects were
time (week 0, 1 and 3), drug (n = 4) and animals (n = 21).
The total residual sum of squares was calculated by subtracting
the between animals, between times sums of squares from the
total sum of squares. This residual was then used to calculate the
average treatment SEM, which indicates variationwithin animals.
The main effect of each drug was determined from the between
times by orthogonal contrasts comparing the average of week
1 and 3 vs. week 0 (control) and using the total residual sums
of squares (see above). Thus, a more robust combined residual
over all groups was used. For intact curves, the duplicates were
averaged in the analysis. An additional analysis was performed
comparing the effects (delta) of each treatment, averaged over the
3 weeks compared to vehicle. P< 0.05 was considered statistically
significant.
Drugs
The compounds used included moxonidine [4-chloro-
5-(2-imidazolin-2-ylamino)-6-methoxy-2-methylpyrimidine]
hydrochloride (Solvay Pharma, Germany), rilmenidine [2-
(dicyclopropylmethyl)-amino-2-oxazoline] dihydrogenophos
phate (I.R.I., Servier, France), clonidine [2-(2,6-dichlorophenyl
amino)-imidazoline] hydrochloride (Boehringer Ingelheim,
U.S.A.), phenylephrine [3-hydroxy-α-((methylamino)
methyl) benzenemethanol] hydro-chloride (Sigma Chemicals,
U.S.A.), sodium nitroprusside [nitrosylpentacyanoferrate
(III)] (Fluka Chemicals, Switzerland), scopolamine methyl
[7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-3-oxa-
9-azoniatricyclononane] bromide (Sigma), normal saline
(Delta West, Bentley, WA, Australia), hydrochloric acid (Ajax
Chemicals, Australia) and sodium hydroxide (Ajax). All drug
doses are expressed as salts. Drugs used for chronic treatment
were dissolved in normal saline. Moxonidine required the
addition of 1M hydrochloric acid and 1M sodium hydroxide to
dissolve the drug and neutralize the solution, respectively.
RESULTS
Chronic Effects of Moxonidine,
Rilmenidine, and Clonidine on MAP, HR,
and BW
The average MAP, HR, and body weight (BW), averaged over
the 4 experimental groups prior to any treatment, were 79 ±
2mmHg, 170 ± 6 beats/min and 2.7 ± 0.09 kg, respectively.
There was no difference in MAP, HR, or BW between the
groups although the baseline HR in the moxonidine group
tended to be slightly lower than the other groups. Subcutaneous
administration of 1mg/kg/day moxonidine and clonidine and
5mg/kg/day rilmenidine reduced MAP by 13 ± 3, 13 ± 2, and
15 ± 2mmHg, respectively, at week 1 of treatment [F(1,25–35) >
21 for each group, P < 0.05]. This hypotension was maintained
in all 3 treatment groups throughout the 3-week infusion period.
Subcutaneous infusions of saline (vehicle) had no effect on MAP
(P > 0.5). Antihypertensive treatment [F(1,25–35) < 4, P > 0.1]
and vehicle [F(1, 30) = 0.8, P = 0.4] had no effect on HR and
rabbits remained in good condition throughout treatment, with
no change in BW.
Chronic Effects of Moxonidine,
Rilmenidine, and Clonidine on Intact
MAP-HR Baroreflex Curves
All three centrally acting antihypertensive agents shifted the
MAP-HR reflex curves to the left in parallel to the hypotension
(Figures 1–3, left panel), resulting in decreases in average
treatment BP50 values (−14 ± 4, −13 ± 3, and −13 ± 5 mmHg
for moxonidine, rilmenidine and clonidine, respectively, P <
0.001) compared to pretreatment baroreflex curves (Tables 1–3).
Rilmenidine reduced the intact baroreflex HR range by an
TABLE 5 | Comparison of chronic effect of moxonidine, rilmenidine and clonidine on intact (vagal and sympathetic) baroreflex curve parameters
compared to vehicle.
Basal Parameters 1 Vehicle 1 Moxonidine 1 Rilmenidine 1 Clonidine
MAP mmHg 0.08± 1.57 −9.27±1.24*** −7.85±1.86*** −6.62± 1.25**
HR b/min 9.83± 6.64 0.28±4.45 −15.47±6.92* 5.4± 8.56
BAROREFLEX PARAMETERS
Lower plateau, b/min 2.56± 6.01 5.99±3.11 9.18±5.81 18.54± 5.72
Upper plateau, b/min −11.54± 7.14 5.5±4.74 −16.16±6.32 5.32± 5.3
Range, b/min −8.97± 5.68 −0.44±5.28 −26.58±6.01* −13.22± 5.97
BP50, mmHg −0.52± 1.39 −13.64±1.94*** −13.43±2.56*** −13.15± 2.19***
Average gain, b/min/mmHg 2.47± 0.7 −1.02±0.7*** 1.14±0.49 2.54± 0.6
Values are mean ± between animal SEM. *P < 0.05, **P < 0.01, ***P < 0.001 for the comparison the effect of vehicle and the other drugs (averaged over the 3 weeks). MAP, mean
arterial pressure; HR, heart rate; BP50, median blood pressure.
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average of 27± 9 beats/min, between weeks 1 and 3 of treatment,
from pre-treatment values [F(1, 64)control vs. drug = 8, P =
0.007] (Figure 2; left panel; Table 2). This effect was due to a
reduction in the upper HR plateau (P = 0.04) with the lower
plateau remaining unaltered. Clonidine reduced intact baroreflex
gain by an average of 26 ± 7 from week 1 of treatment (Table 3)
but so did vehicle treatment (−23 ± 7%, Table 4). No other
changes were seen in the baroreflex parameters for these two
groups, whilst moxonidine was the only treatment that had no
effect on any parameters of the intact baroreflex curve (Table 1).
A comparison between treatments showed that all treatments
decreased BP50 but that only rilmenidine reduced the HR range
compared to vehicle (Table 5).
Chronic Effects of Moxonidine,
Rilmenidine, and Clonidine on the
Sympathetic Component of the MAP-HR
Baroreflex Curves
Intravenous methscopolamine, by blocking cardiac vagal activity,
increased HR in all four experimental groups, at weeks 0, 1,
and 3 of treatment (P < 0.01). Assessment of the remaining
sympathetic component of the cardiac baroreflex at these
times showed that antihypertensive treatment with moxonidine,
rilmenidine and clonidine caused the baroreflex curves, at weeks
1 and 3, to be shifted to the left of the pre-treatment sympathetic
curve for each group (Figures 1–3; right panels). This leftward
shift reflects the hypotension produced by the agents and thus,
the BP50 values for these curves were correspondingly lower than
at week 0 (Tables 1–3). The major effect of vagal blockade on
the baroreflex was to reduce the HR range by two thirds (66%)
of the intact curve, principally by an increase in the level of
the lower HR plateau. Moxonidine, rilmenidine, and clonidine
all caused decreases in the lower plateau of the sympathetic
baroreflex curves, fromweek 1 of treatment (P< 0.01), compared
with their respective pre-treatment curves (Figures 1–3; right
panels; Tables 1–3). With rilmenidine treatment, this decrease
in the lower plateau was accompanied by a similar decrease in
the upper plateau, averaging 27± 10 beats/min, between weeks 1
and 3 of treatment, resulting in a parallel downward shift of the
sympathetic curves with no change in HR range (P control vs.
drug = 1). This was probably due to a baroreflex independent
inhibition of cardiac sympathetic activity. In contrast, this
decrease in lower plateau was not accompanied by a similar
decrease in the upper plateau with moxonidine (P control vs.
drug = 1) and clonidine treatment (P control vs. drug =
0.06), with the upper plateau remaining unaltered, resulting
in an increase in the sympathetic HR range in moxonidine
treated animals by an average of 34 ± 10% (P = 0.01), but no



















FIGURE 4 | Average sigmoid curves indicating the relationship between mean arterial pressure (MAP, mmHg) and heart rate (HR, beats/min) for the
intact baroreflex curves (left panel) and the sympathetic and calculated vagal baroreflex curves (right panel) in seven conscious rabbits before (weeks
0, black line, black circles on all panels) and at weeks 1 (blue line, blue square on all panels) and 3 (red line, red triangle on all panels) of vehicle
treatment. Symbols on curves represent resting values Error bars are average SEM indicating variation between animals calculated from the ANOVA.
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TABLE 6 | Comparison of chronic effect of moxonidine, rilmenidine and clonidine on sympathetic baroreflex curve parameters compared to vehicle.
Basal Parameters 1 Vehicle 1 Moxonidine 1 Rilmenidine 1 Clonidine
MAP mmHg 1.95± 3.44 −8.36± 2.56* −10.69± 1.9** 1.58± 3.53
HR b/min −11.5± 5.1 −39.8± 7.2* −40.6± 8.7* −36.7± 10.6*
BAROREFLEX PARAMETERS
Lower plateau, b/min −11.1± 6 −22.5± 7.3 −26.2± 6.6 −23.7± 8.3
Upper plateau, b/min −7.3± 9.4 5.6± 8.4 −27.3± 7.3 −22± 11.7
Range, b/min 3.8± 7.8 28.1± 10.2 −1.1± 7.5 1.7± 6.7
BP50, mmHg 4.01± 4.51 −16.94± 2.63** −20.46± 3.06*** −13.9± 5.03**
Average gain, b/min/mmHg −1.2± 0.85 −3.13± 0.93 0.12± 0.73 −2.36± 1.1
Values are mean ± between animal SEM. *P < 0.05, **P < 0.01, ***P < 0.001 for the comparison the effect of vehicle and the other drugs (averaged over the 3 weeks). MAP, mean
arterial pressure; HR, heart rate; BP50, median blood pressure.
98 ± 41% (P = 0.04) increase in the sympathetic baroreflex
gain, compared with pre-treatment values, due mostly to the
increase in HR range. Vehicle treatment did not affect any
sympathetic baroreflex parameters, with the curves at weeks 1
and 3 being superimposed on the pre-treatment curve (Figure 4;
right panel).
A comparison between treatments on the sympathetic curves
showed that all treatments decreased BP50 but there were
no other effects of baroreflex parameters compared to vehicle
(Table 6).
Chronic Effects of Moxonidine,
Rilmenidine, and Clonidine on the Vagal
Component of the MAP-HR Curves
(Calculated)
The calculated vagal curves as shown in Figures 1–4, right panels,
and the parameters, indicated in Tables 1–4, were calculated
by subtracting the sympathetic sigmoid curve from the original
intact curve and therefore represent approximately 66% of the
normal baroreflex HR range. Moxonidine and rilmenidine both
caused a decrease in the calculated vagal HR range, similarly at
weeks 1 and 3 [F(1, 64) control vs. drug = 4, P = 0.04, F(1, 64)
control vs. drug = 5, P = 0.04, respectively], averaging 29 ±
13 and 25 ± 12 beats/min. However, this decrease in range
was not due to any significant changes in either the upper or
lower plateaus alone. As seen in the intact curve, clonidine and
vehicle treatment similarly reduced the gain of the calculated
vagal baroreflex [F(1, 64) control vs. drug= 15, P= 0.0003, F(1, 64)
control vs. drug = 8, P = 0.005, respectively], with average
changes of 65 ± 16 and 46 ± 21%, respectively, after 1 week of
treatment (Tables 3, 4). As there were no changes in gain in the
sympathetic curve, we have confirmed that the reductions in gain
seen in the intact curves with clonidine and vehicle treatment
were due to a reduction in the gain of the vagal component of
the baroreflex.
Contribution of Vagus and Sympathetic to
HR
At the end of the 3-week treatment period, the contribution of
the cardiac vagus to resting HR was maintained in all treatment


























Veh Mox Ril Clo
FIGURE 5 | Average contribution of the sympathetic and vagal
influences on resting heart rate at 1 and 3 weeks of treatment in
vehicle (Veh), moxonidine (Mox), Rilmenidine (Ril) and clonidine (Clo).
Vagal contribution calculated as the change in heart rate induced by the
administration of methscopolamine. Sympathetic component calculated as the
heart rate under methscopolamine minus the intrinsic heart rate. The latter was
estimated as 200 b/min according to the literature for rabbits at that body
weight (Opthof, 2000). **P < 0.01 and ***P < 0.001 for the effect of treatment
compared to vehicle.
moxonidine and clonidine treated rabbits (−40 ± 10 b/min and
−42 ± 10 b/min respectively) compared to baseline. However,
this was not different to the change observed in the vehicle
group (−21 ± 13 b/min). Nor was there any difference between
the absolute values between groups (Figure 5). The contribution
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of the cardiac sympathetic to resting HR was reduced by all 3
treatments (Figure 5).
DISCUSSION
The present study examined the chronic effects of moxonidine,
rilmenidine and clonidine on the vagal and sympathetic
components of the cardiac baroreflex in conscious rabbits. We
found that all drugs shifted curves to the left in line with the
hypotension which is an expected finding related to baroreceptor
resetting. This is a well-known phenomenon and does not
usually involve a change in central baroreflex function (Dorward
et al., 1982). However, despite the similar degree of hypotension
produced by all three agents, there were unexpectedly quite
disparate effects of the drugs on cardiac baroreflexes. Rilmenidine
and moxonidine reduced HR range of the vagal curves while
clonidine and vehicle treatment had little effect. For rilmenidine,
this was also observed in the intact curves (vagal and sympathetic
combined) but not for moxonidine. Moxonidine increased the
range of the sympathetic curves while rilmenidine, clonidine and
vehicle treatments showed no change in this parameter over 3
weeks. By contrast, all 3 agents reduced the lower plateau of the
sympathetic baroreflex and also the sympathetic component of
the resting HR. Thus, the resting value moved from the middle
of the curve to lie much closer to the lower plateau. There was
also a tendency for a lesser vagal contribution to resting HR
which to some degree offset the reduced sympathetic resulting
in no long term change in basal HR in treated rabbits. Thus,
moxonidine, and to a lesser extent rilmenidine, increased the
proportion of the sympathetic component in the baroreflex,
whilst decreasing the vagal component. Not only was the range
of the reflex affected but the gain of the sympathetic curve was
doubled by moxonidine over the 3-week treatment period. A
similar trend was observed with clonidine but it did not reach
the significance value (P= 0.06). Thus, second generation agents
rilmenidine and moxonidine attenuated the vagal component of
the curve whilemoxonidine produced amarked facilitation of the
cardiac sympathetic curve. Importantly, these results suggest that
chronic effects on baroreflexes cannot be assumed by the class of
agent in relation to centrally acting antihypertensive drugs and
need to be individually assessed.
Rilmenidine and to a lesser extent clonidine treated
animals exhibited a downward shift of the cardiac sympathetic
reflex curve at weeks 1 and 3 of treatment without any
effect on the sympathetic reflex range. Hence these changes
are due to baroreflex independent alterations. Moxonidine
reduced the lower plateau like rilmenidine but the upper
plateau was not altered. Thus, there was an increase in the
sympathetic HR range. Moxonidine also increased the gain
of the sympathetic baroreflex curve, suggesting that with
moxonidine treatment, cardiac sympathetic activity is more
sensitive to changes in pressure. Thus, with much reduced
basal sympathetic activity after moxonidine, the capacity to
increase HR with a hypotensive challenge is increased. The
effects of moxonidine on the baroreflex, as determined in
this chronic study, suggest that moxonidine should have a
more prominent role in hypertensive therapy especially since
acute studies have reported a beneficial inhibition of the
cardiac sympathetic particularly in relation to treating the
sympathetic overactivity related to hypertension (Head and
Malpas, 1997). These cardiac sympatho-inhibitory properties
also applied to rilmenidine and clonidine except that the
sympathetic range was maintained and not increased. Also in all
cases the contribution of the sympathetic to the resting HR was
reduced. The difference between moxonidine and rilmenidine
and clonidine is that the latter two drugs will produce a
lesser increase in cardiac sympathetic activation in the presence
of hypotension. The clinical implications of the sympathetic
modulation effect of moxonidine if translated to humans may
have contributed to the issues of higher mortality in heart
failure patients observed in the MOXCON trial (Cohn et al.,
2003).
We have previously assessed the acute effects of these agents
on vagal and sympathetic components of the baroreflex in
conscious rabbits (Godwin et al., 1998). A comparison of the
published acute and the current chronic effects has been made
in Table 7. Surprisingly absolutely none of the acute effects
of these agents has been observed during chronic treatment.
Acutely, rilmenidine and clonidine increased the vagal range
of the reflex which is the opposite in the case of rilmenidine
to the chronic effects. Rilmenidine also acutely reduced the
range of the sympathetic curve but had no effect chronically.
Moxonidine on the other hand acutely reduced the gain of
the intact baroreflex curves but had no effect chronically.
This was due to a chronic increase in the gain and range
of the sympathetic component and a reduction in the range
of the vagal component. None of these effects of moxonidine
was observed acutely. Clonidine acutely increased the vagal
component of the baroreflex curves which has been suggested
to be due to activation of α2-adrenoceptors but had no effect
chronically. The explanation for this may be due to a down
regulation in contribution of central α2-adrenoceptors which
have been shown to reduce in number with as little as 6
days treatment (Hamilton et al., 1992). Our own study using
antagonists at imidazoline and α2-adrenoceptors during chronic
administration of moxonidine, clonidine and rilmenidine found
no selectivity for imidazoline receptors over α2-adrenoceptors
for HR effects suggesting they were largely mediated through
the latter receptor (Parkin et al., 2003). This contrasts the
hypotension which for moxonidine, rilmenidine, and clonidine
is largely mediated through imidazoline receptors (Parkin et al.,
2003). Interestingly, the antagonists after chronic treatment
caused a rebound tachycardia in rilmenidine and clonidine
groups but no effect in moxonidine treated rabbits, suggesting
that there was actually a greater tonic inhibitory influence of
α2-adrenoceptors (Parkin et al., 2003). Given the inhibition
of the sympathetic component particularly by rilmenidine (see
Figure 5), this suggests that the cardiac sympatho-inhibition is
mediated by activation of α2-adrenoceptors.
The disparate effects of acute and chronic administration are
a salient reminder of the value in performing studies which
more closely reflect the long term treatments usually associated
with hypertension. Surprisingly there have been very few studies
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TABLE 7 | Comparison of chronic and acute effect of moxonidine, rilmenidine and clonidine on baroreflex curve parameters.
Moxonidine Rilmenidine Clonidine
Acute Chronic Acute Chronic Acute Chronic
BP50, mmHg
Basal HR – – – –
Range V+S – – – –
Range V – –
Range S – – – –
Average gain V+S, – – – – –
Average gain V, – – – – – –
Average gain S, – – – –
Up arrows indicate an increase in each parameter compared to baseline either acutely (data from Godwin et al., 1998) or as an average at 1 and 3 weeks post chronic treatment. Down
arrows indicate a decrease in each parameter. V+S indicates intact curve with both vagal and sympathetic components. V indicates the calculated vagal contribution and S indicates
the sympathetic contribution after blockade with methscopolamine.
examining baroreflex changes with chronic treatment with any
of the centrally acting agents. A study in conscious dogs using
15 days of a single daily bolus dose of rilmenidine reported no
change in the cardiac baroreflex with chronic treatment but an
increase in gain with acute treatment (Spiers et al., 1990). By
contrast we did not observe any change in gain either acutely
(Godwin et al., 1998) or chronically (current study) in conscious
rabbits. A 4 week treatment of 8 mildly hypertensive patients
demonstrated a small increase in baroreflex sensitivity after 4
weeks of rilmenidine but this study was an open label trial with no
randomisation, crossover or placebo thus making interpretation
difficult (Finta et al., 2006).
The main strengths of our study are the use of a within animal
experimental design, use of conscious animals, assessment of
intact and sympathetic components of the baroreflex curve, use
of full sigmoidal curves rather than straight line regression and
the inclusion of a vehicle time control. The limitations are that
we used only one dose for each drug but these were based
on dose response curves performed with chronic treatment in
our previous studies (Parkin et al., 2003). All drugs produced a
similar degree of hypotension which enabled us to compare them
across all the baroreflex variables. A further limitation is that we
estimated the vagal contribution by subtracting the sympathetic
component from the intact curve rather than determining it
directly. However, this technique has been used successfully
previously (Godwin et al., 1998).
In conclusion, our study shows that chronic treatment
with first and second generation antihypertensive agents
produces small but important modulation of the baroreflex
control of HR. The main effects were to shift the curves
leftward and inhibit basal cardiac sympathetic activity. Second
generation agents moxonidine and rilmenidine but not first
generation agent clonidine chronically shifted the balance of
baroreflex control of HR toward greater sympathetic and lesser
vagal influences. These changes if translated to hypertensive
subjects, may not be particularly helpful in view of the
already reduced vagal and greater sympathetic activity in
hypertension. First generation agent clonidine had virtually
no chronic effect on cardiac baroreflexes in the present
study.
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